Estradiol: the floor is real, the ceiling is invented
The test most men are given cannot measure male estradiol accurately. The evidence that it can be too low is strong. The evidence that it can be too high does not exist.
More is claimed about this test, with less behind it, than about anything else on a male hormone panel.
Two things are true at once and they point in opposite directions from what most men are told. There is good randomised evidence that a man’s estradiol can be too low, and the number is remarkably consistent across three different outcomes. There is essentially no evidence that it can be too high — and the trial universally cited to justify suppressing it found the opposite of what it is used to argue.
Before either of those matters, though: the test most men are given cannot measure male estradiol reliably.
What it measures
Estradiol is the main biologically active estrogen. In men most of it is made not by the testis but by aromatase acting on testosterone in fat, liver, muscle, bone and brain.
The commonly quoted figure is that 80% comes from that peripheral conversion. We can trace it only to a 1979 isotope-dilution study of four men, which supports something closer to three-quarters or more — and no modern method has revisited it. The direction is not in doubt. The precision of the number is not real.
One thing worth knowing that almost nobody measures: estrone, not estradiol, is the numerically dominant estrogen in men. In a large mass-spectrometry series, median estrone exceeded median estradiol, and the free estrone concentration was roughly twice the free estradiol.
The assay problem, which comes first
At the concentrations found in men — the low tens of pg/mL — the ordinary immunoassay is not a slightly noisy version of the right answer. It is partly measuring something else.
In 101 healthy men measured by five commercial direct immunoassays against mass spectrometry, all five had positive biases, ranging from 6% to 74%. Two of the five could not detect estradiol at all in a substantial share of male samples — one detected it in 53%, another in 72%. And mass spectrometry, but none of the immunoassays, correlated with the man’s own testosterone and SHBG, which is what you would expect a real estradiol measurement to do.
In 3,174 European men compared against gas chromatography-mass spectrometry, the immunoassay’s correlation with the reference method below about 11 pg/mL was r = 0.32 — effectively none. Its sensitivity for detecting a genuinely low male estradiol was 13.3%. The authors’ conclusion was that the immunoassay “may only be suitable for the detection of high E2 in men.”
A third study, across three cohorts totalling more than 6,000 men, found something more troubling: immunoassay estradiol correlated with C-reactive protein while mass-spectrometry estradiol did not, and an apparent association between estradiol and vascular disease disappeared once CRP was accounted for. The authors read it as interference. An inflamed man’s immunoassay estradiol reads high partly because he is inflamed.
Precision is not accuracy. The same comparison found the immunoassays were more reproducible than mass spectrometry while being biased upward. A tightly reproducible wrong number is the worst possible input to a dose decision.
Evidence: Established.
What “sensitive estradiol” actually means
At the major American reference laboratories, the test sold as “estradiol, sensitive” is a mass spectrometry assay — one national laboratory lists its method explicitly as liquid chromatography–tandem mass spectrometry, with an adult male interval of 8.0 to 35.0 pg/mL, and states in its own catalogue that a sensitive mass-spectrometry assay “is preferred over direct immunoassays because of its greater sensitivity and lesser interference by other steroids.”
But “sensitive” is an ordering word, not a regulated method designation. Low-detection-limit immunoassays and older extraction radioimmunoassays have carried similar names. The only way to know is to read the method line on the report.
A useful cross-check: the CDC runs a standardization program for estradiol, requiring a bias within ±12.5% above 20 pg/mL and ±2.5 pg/mL at or below 20 pg/mL. Every laboratory currently certified under it for estradiol uses mass spectrometry. Not one routine clinical immunoassay platform appears on the list.
There is no harmonized male reference range
Testosterone has one. Estradiol does not, and the disagreement is concentrated exactly where it matters.
| Source | N | Male interval |
|---|---|---|
| A CDC-traceable LC-MS/MS method, 2019 | 64 | 3.3 – 37.0 pg/mL |
| A large LC-MS/MS reference study, 2020 | 157 men aged 31–61 | 13.6 – 40.9 pg/mL |
| A national reference laboratory’s sensitive assay | — | 8.0 – 35.0 pg/mL |
The upper bounds cluster tightly at 35 to 41. The lower bounds differ by a factor of four. Any claim that a man’s estradiol should sit inside a narrow window has to survive the fact that three properly conducted mass-spectrometry laboratories cannot agree where the bottom of normal is.
For conversion: pg/mL × 3.671 = pmol/L.
What estradiol actually does in men
The decisive evidence is a single trial, and it is a good one.
Four hundred healthy men aged 20 to 50 had their own gonadal steroid production shut down with goserelin, then received one of five doses of testosterone gel — from placebo up to 10 grams daily — for 16 weeks. Half of them also received anastrozole, blocking conversion to estradiol. Estradiol was measured by mass spectrometry down to 1.25 pg/mL. That design separates the effects of testosterone from the effects of its estrogen metabolite in a way no observational study can.
The findings, in the authors’ own summary: “Androgen deficiency accounted for decreases in lean mass, muscle size, and strength; estrogen deficiency primarily accounted for increases in body fat; and both contributed to the decline in sexual function.”
Specifically, blocking aromatization significantly increased body fat percentage, subcutaneous fat and intra-abdominal fat, and significantly decreased sexual desire and erectile function — while making no difference at all to lean mass, thigh muscle area or leg-press strength.
The sentence most worth carrying out of that paper: in men with a testosterone of 200 to 400 ng/dL, sexual desire fell by 13% if estradiol was 10 pg/mL or above, and by 31% if it was below 10.
Evidence: Established.
The floor: about 10 pg/mL
Three different outcomes, from the same randomised program, converge on the same number.
Sexual desire. 13% decline above 10 pg/mL versus 31% below.
Vasomotor symptoms. Hot flushes were reported at 38% of visits when estradiol was 5 to 9.9 pg/mL, against 16% at 10 to 14.9 pg/mL. The authors’ conclusion: “Estradiol deficiency is the key mediator of VMS in hypogonadal men.”
Bone. In the companion bone analysis, spine bone density fell substantially in every testosterone dose group in which aromatization was suppressed, independent of testosterone dose. The threshold sentence reads: “Estradiol levels above 10 pg/ml and testosterone levels above 200 ng/dl were generally sufficient to prevent increases in bone resorption and decreases in BMD in men.”
This is the one estradiol claim in the whole field that the primary literature fully supports. Note which direction it points: it is an argument against suppressing estradiol, not for it.
The ceiling: there isn’t one
The same trial is routinely cited to justify keeping estradiol in a narrow band. Read what it actually found at the top end.
The 10-gram group reached a mean estradiol of 33.3 pg/mL — the highest in the study. That group was the only one whose body fat percentage decreased, the only one whose thigh muscle area increased significantly, and it recorded the highest sexual desire scores.
The trial found benefit that increased monotonically up to 33 pg/mL and identified no upper limit at all. The floor it established is real and reproducible. The ceiling is an invention laid on top of it.
We have looked for, and not found, any primary evidence establishing an optimal upper bound for male estradiol, and none for symptoms attributable to a high estradiol at concentrations reachable on ordinary testosterone therapy.
Evidence: Unsupported — for the claim that there is a defined upper limit.
Estradiol, not testosterone, builds male bone
Two experiments of nature settle this, and they are worth knowing because they are so clean.
A man with a mutation disabling the estrogen receptor was 204 cm tall with epiphyses that had never closed, normally masculinised, with normal testosterone and elevated estradiol — and a lumbar spine bone density 3.1 standard deviations below the mean for age-matched normal women. Six months of transdermal estrogen, producing a tenfold rise in his free estradiol, did nothing, because the receptor could not read it.
A man with aromatase deficiency had a testosterone of 2,015 ng/dL — roughly double the top of any normal range — with estradiol below 7 pg/mL. At a chronological age of 24 his bone age was 14, his epiphyses were unfused, he was 204 cm tall, and his distal radius bone density was 4.7 standard deviations below age- and sex-matched normal men.
Enormous testosterone did not protect his skeleton. The estrogen it could not be converted into was what mattered.
Evidence: Established.
The cohort evidence linking a man’s estradiol level to fracture risk is less settled than this makes it sound, and we will say so: one large Swedish cohort found a nonlinear relationship with a strong effect below 16 pg/mL and free estradiol independently predictive where free testosterone was not — while a later, larger analysis combining Swedish and Hong Kong cohorts found that neither estradiol nor testosterone predicted incident clinical vertebral fractures. The randomised evidence above is stronger than either.
Gynecomastia
The reasoning runs: estradiol causes breast tissue, so estradiol must be suppressed. The evidence does not support the first step as stated.
No published estradiol threshold for gynecomastia in men exists. We searched for one specifically.
What the case-control literature shows instead: in 47 young men with idiopathic gynecomastia against 30 controls, the hormone profiles including estradiol were statistically similar. In 126 men with gynecomastia against 94 controls, 46% were idiopathic, and the standout finding was elevated SHBG across every group including the idiopathic one, alongside BMI. In a study of 40 men with ultrasound-confirmed gynecomastia, estradiol was measured and does not appear among the independent associations — those were lipoatrophy, hepatitis C, and hypogonadism, at an adjusted odds ratio of 7.6.
Gynecomastia in men tracks the balance between androgen and estrogen signalling, SHBG, and adiposity. It does not track a number on a report.
Evidence: Limited.
Aromatase inhibitors
This is where the page has practical consequences, so we will be direct about what the trials show.
They do raise testosterone. In a one-year trial randomising 69 older men to anastrozole 1 mg daily or placebo, testosterone in the treated arm rose from 319 to 524 ng/dL at three months.
They also cost bone. In that same trial, over one year, spine bone density fell in the anastrozole group and rose in the placebo group — and the estradiol drop that produced it was modest, from 15 to 12 pg/mL. A separate trial comparing testosterone gel, anastrozole and placebo in older men found that testosterone improved lumbar spine bone density and anastrozole did not, concluding that aromatization of testosterone “is required for maintaining BMD in older men with low-T levels.”
The evidence for using one alongside testosterone therapy is one negative trial. Forty men with epilepsy and hypogonadism were randomised to testosterone plus anastrozole or testosterone plus placebo for three months. Sexual function normalised in 72.2% versus 47.4% — not statistically significant. That is the closest thing to a randomised test of the practice that exists, and it missed its primary endpoint.
The evidence for treating testosterone-associated gynecomastia with anastrozole, as far as we can trace it, is a 2004 report of two patients.
What the bodies say. The AUA permits aromatase inhibitors for one purpose only — men with testosterone deficiency who want to preserve fertility — as a conditional recommendation on Grade C evidence. The EAU calls them off-label, says “the evidence published so far is poor,” and warns that “long-term use of these agents can lead to reduced bone density and development of osteoporosis.” The VA states that they “raise the risk of ischemic cardiovascular events in patients with preexisting cardiovascular disease, increase central body fat, and decrease bone mineral density,” and that they have not been studied in randomised placebo-controlled trials beyond a year.
Evidence: Unsupported for routine use with testosterone therapy; Limited for fertility indications.
A correction that runs the other way
Selective estrogen receptor modulators — tamoxifen, clomiphene — are often grouped with aromatase inhibitors as “estrogen control.” They do the opposite to the measurement. Tamoxifen significantly raised total estradiol in a crossover trial, and by 1.3 to 2.2 times baseline in another series. In a head-to-head randomised comparison, clomiphene raised estradiol while anastrozole lowered it.
SERMs block the receptor while raising the ligand. If you are on one, a high estradiol on your report is the drug working, not the drug failing.
When it should actually be ordered
No major guideline recommends routine estradiol measurement in men on testosterone therapy. We checked all four.
| Body | Position |
|---|---|
| Endocrine Society (2018) | Monitoring is testosterone, hematocrit and prostate cancer risk. Estradiol is not among them |
| AUA (2018, validity confirmed 2024) | One statement, Expert Opinion: measure estradiol in men “who present with breast symptoms or gynecomastia prior to the commencement of testosterone therapy.” Monitoring is testosterone every 6 to 12 months — estradiol absent |
| EAU (2026) | Estradiol appears in neither the diagnostic nor the monitoring recommendation table |
| VA, Recommendations for Use (January 2026) | Monitoring is testosterone, hemoglobin and hematocrit, and PSA at 3 to 6 months and again at 12. Estradiol absent |
The one indication any of them gives is the AUA’s: breast symptoms or gynecomastia, before starting. That is a narrow, symptom-triggered, pre-treatment test — not a titration target.
What raises and lowers it
Raises. Testosterone therapy, dose-dependently and reliably — across the randomised dose groups above, mean estradiol ran 3.6, 7.9, 11.9, 18.2 and 33.3 pg/mL. Acute hCG stimulation, which raised estradiol by about 168% within 24 hours in one series, faster and proportionally more than it raised testosterone. hCG-secreting testicular tumours. SERMs, as above.
Adiposity is more complicated than it sounds. Aromatase protein is higher in abdominal obesity, but in 315 healthy drug-free men measured by mass spectrometry, estrone rose with BMI and estradiol did not — estradiol was given a BMI-independent reference interval. The estrogen that moves with body fat is the one nobody orders.
Aging. Also not what is usually claimed. The best mass-spectrometry series found male estradiol flat across adult ages. The literature is not unanimous, but “estradiol climbs as men age” is not established.
Lowers. Aromatase inhibitors, modestly in a man with an intact axis — roughly 20 to 50%, not ablation. Genetic aromatase deficiency, to below 7 pg/mL.
We have deliberately not listed liver disease, alcohol, hyperthyroidism, spironolactone or ketoconazole as things that raise estradiol, because we could not find primary human data showing that they raise the measured hormone. Several of them plausibly shift the androgen-to-estrogen balance without changing serum estradiol, which is a different claim.
Related
The Lab Library · Total testosterone · SHBG · Testosterone replacement therapy
Questions patients ask
My estradiol is high on testosterone, so I need an aromatase inhibitor.
More complicated than it sounds — and probably not.
What the evidence showsThe trial that established what estradiol does in men found the highest-estradiol group, at a mean of 33.3 pg/mL, had the best body composition and the highest sexual desire. Blocking aromatization increased body fat, increased both subcutaneous and intra-abdominal fat, decreased sexual desire and erectile function, and caused spine bone density to fall independent of testosterone dose. The only randomised trial of an aromatase inhibitor alongside testosterone therapy missed its primary endpoint.
What remains uncertainWhether there is any estradiol level in a man on ordinary replacement doses that warrants intervention. Nobody has identified one.
Bottom lineA high number on a report is not a reason to take a drug that reliably costs you bone.
Moderate against routine use
My estradiol came back at 45, which is way too high.
On which assay? If it was a standard immunoassay, that number may not mean what it appears to.
What the evidence showsFive commercial direct immunoassays measured against mass spectrometry in 101 men all read high, by 6% to 74%. Immunoassay estradiol also tracks C-reactive protein while mass-spectrometry estradiol does not, so inflammation inflates it. And the immunoassay's correlation with the reference method at low male concentrations was 0.32.
What remains uncertainHow far off your particular result is. The bias is not a fixed offset you can subtract.
Bottom lineRead the method line on the report before reacting to the number.
Strong
There's an optimal estradiol range for men, and I should titrate to it.
There is a floor. There is no established ceiling and no established range.
What the evidence showsThree separate outcomes — sexual desire, hot flushes and bone resorption — converge on about 10 pg/mL as the level below which things get worse. Above it, the randomised data show benefit continuing up to the highest level studied. Meanwhile the three best mass-spectrometry laboratories publish lower limits of normal that differ fourfold, from 3.3 to 13.6 pg/mL.
What remains uncertainWhether a genuine upper limit exists at concentrations higher than any trial has produced. Nobody has studied it.
Bottom lineWorry about estradiol being too low. That is where the evidence is.
Moderate
Estradiol causes gynecomastia, so keeping it down prevents breast tissue.
No published estradiol threshold for gynecomastia in men exists, and we looked for one.
What the evidence showsIn 47 men with idiopathic gynecomastia versus 30 controls, hormone profiles including estradiol were statistically similar. In 126 cases versus 94 controls, 46% were idiopathic and the standout findings were SHBG and BMI. In 40 men with confirmed gynecomastia, the independent associations were lipoatrophy, hepatitis C and hypogonadism — estradiol was measured and is not among them.
What remains uncertainWhat does drive it in an individual man. Balance, SHBG and adiposity are better candidates than a serum number.
Bottom lineReal condition, real distress, wrong lever.
Limited
Testosterone is what protects a man's bones.
It is mostly the estradiol made from it.
What the evidence showsA man with aromatase deficiency and a testosterone of 2,015 ng/dL — double the top of normal — had unfused epiphyses at 24 and a distal radius bone density 4.7 standard deviations below normal men. A man who could not respond to estrogen at all had a spine density 3.1 standard deviations below normal women, despite normal testosterone. In the randomised trial, spine bone density fell in every testosterone dose group in which aromatization was blocked.
What remains uncertainThe exact fracture threshold. Two large cohorts disagree — one found a strong effect below 16 pg/mL, a later and larger one found estradiol did not predict vertebral fracture at all.
Bottom lineThis is the strongest single argument against suppressing a man's estradiol.
Strong
I should get estradiol checked at every visit while I'm on testosterone.
Not one of the four major guidelines recommends it.
What the evidence showsThe Endocrine Society monitors testosterone, hematocrit and prostate risk. The AUA monitors testosterone every 6 to 12 months and mentions estradiol only in one Expert Opinion statement, for men with breast symptoms before starting. The EAU has estradiol in neither its diagnostic nor its monitoring table. The VA monitors testosterone, hemoglobin and hematocrit, and PSA.
What remains uncertainNothing about what the documents say. What is uncertain is whether routine measurement would help, and nobody has tested it.
Bottom lineOrder it for a reason — breast symptoms, or an unexplained problem. Not as a habit.
Strong
Ready for testosterone care built on a diagnosis?
The first step is a full endocrine evaluation, not a prescription. We see patients across San Diego County and welcome referrals from other physicians.
